Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-08-15Clinical Trial Update: A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer [Phase 3]
A Phase 3 clinical trial update for navicixizumab in platinum-resistant ovarian cancer is underway, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with carboplatin for relapsed or refractory ovarian, fallopian tube, or p…
-
EMA guidance · 2022-07-22EMA recommends restricting use of cancer medicine Rubraca
EMA recommends restricting the use of the cancer medicine Rubraca (rucaparib) to specific patient groups due to safety or effectiveness cons…
-
CLINICAL_TRIALS trial_result · 2022-06-24Clinical Trial Update: Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update for paclitaxel and ganetespib in recurrent ovarian, fallopian tube, or primary peritoneal cancer; study terminated wit…
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 [Phase 1, Phase 2]
Phase 1/2 trial evaluating NY-ESO-1–targeted T-cell therapy with or without decitabine in patients with NY-ESO-1–expressing advanced cancers…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy [Phase 3]
Phase 3 trial evaluating Fluzoparib with or without Apatinib versus placebo for maintenance in advanced ovarian cancer after response to fir…
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas [Phase 2]
Phase 2 trial investigating autologous dendritic cells loaded with autologous tumor-associated antigens for advanced epithelial ovarian carc…
-
FDA approval · 2022-04-13FDA Approved: ALYMSYS — Original Application (Amneal Pharmaceuticals LLC)
FDA approves ALYMSYS as a biosimilar to bevacizumab (bevaczizumab-maly) from Amneal Pharmaceuticals LLC under an original Biologics License …
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients [Phase 3]
Phase 3 ARIEL4 trial comparing rucaparib to chemotherapy in BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancer has completed …
-
CLINICAL_TRIALS trial_result · 2022-02-07Clinical Trial Update: Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]
A clinical trial evaluating topotecan in combination with gefitinib (Iressa) for ovarian, peritoneal, or fallopian tube cancers has complete…
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery [Phase 2]
Phase 2 trial update on IGFBP-2 vaccine with combination chemotherapy for stage III-IV ovarian, fallopian tube, or primary peritoneal cancer…
-
CLINICAL_TRIALS withdrawal · 2021-12-23Clinical Trial Update: DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma [Phase 3]
Phase 3 trial of DCVAC/OvCa with standard of care for relapsed ovarian/fallopian tube/peritoneal cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients [Phase 2]
Phase 2 study evaluating pembrolizumab in recurrent, platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers with CPS > 1…
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update for an autologous oxidized tumor cell lysate vaccine in recurrent ovarian/fallopian tube/primary peritoneal cancer; tr…
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]
Phase 1 clinical trial update for a vaccine therapy in ovarian epithelial, primary peritoneal, or fallopian tube cancer with completed statu…
-
FDA approval · 2021-09-09FDA Approved: TALZENNA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TALZENNA (talazoparib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2021-09-02Clinical Trial Update: Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 study examining whether physical activity tracked by Fitbit Charge 2 improves quality of life in participants with recurrent ovarian…
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 3]
A Phase 3 trial comparing Niraparib-TSR-042 (Dostarlimab) to physician's choice chemotherapy in recurrent ovarian/fallopian tube/primary per…
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination [Phase 1, Phase 2]
A phase 1/2 trial comparing carboplatin-paclitaxel-bevacizumab with alternative regimens including rucaparib, selected by HRD status, in adv…
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients [Phase 3]
Phase 3 trial comparing trabectedin (ET-743) to clinician's choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube …
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites [NA]
Clinical trial update for Canady Helios cold plasma scalpel at surgical margins and macroscopic tumor sites; status and results data are unc…
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer [Phase 2]
A Phase 2 trial evaluating pembrolizumab in combination with pegylated liposomal doxorubicin for recurrent platinum-resistant ovarian, fallo…
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC [Phase 2]
Phase 2 clinical trial evaluating efficacy and safety of SG001 in combination with PLD for platinum-resistant relapsed epithelial ovarian ca…
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) [Phase 2]
Phase 2 study ARIEL2 evaluating rucaparib in platinum-sensitive relapsed high-grade ovarian/fallopian tube/primary peritoneal cancer complet…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]
Clinical trial update for DPX-Survivac in recurrent ovarian-related cancers, spanning Phase 1 and Phase 2.